利用指数流加补料高密度发酵产β-呋喃果糖苷酶重组大肠杆菌

【目的】对重组大肠杆菌BL21(DE3)/pET22b-β-ffase进行高密度发酵产β-呋喃果糖苷酶工艺研究。【方法】比较溶氧反馈补料和指数流加补料对重组菌发酵产酶的影响,对不同比生长速率和诱导时机进行优化。【结果】确定了双阶段指数流加过程中重组菌生长的比生长速率,分别控制诱导前期比生长速率为0.20 h~(-1),诱导后期比生长速率为0.13 h~(-1),诱导时机为指数中期。获得细胞干重约为51 g/L,最高酶活达到1.79×10~5 U/L,单位菌体产酶量为3 510 U/g,单位产酶速率达到3.58×10~4 U/(L·h),生物量、单位菌体产酶量和产酶速率分别是指数流加未优化前的1.8、1.7和3.0倍。【结论】双阶段指数流加补料工艺能有效提高β-呋喃果糖苷酶的产酶量,为β-呋喃果糖苷酶的进一步工业化奠定基础。     

溶氧反馈分批补料高密度培养人骨形成蛋白-2工程菌

对表达人骨形成蛋白－2成熟肽的基因工程大肠杆菌E.coli DH5α/pDH-B2m在500mL摇瓶中进行了培养条件的摸索实验,并在此基础上扩大至NBS Bioflo IV20L发酵罐,利用溶氧反馈－分批补料培养技术：在培养过程中保持适当的溶解氧（40％）,以溶氧值在线反馈控制搅拌速度及流加补料培养基,使细菌保持适当的比生长率,成功地进行了工程菌的高密度培养,最终菌体密度达OD600＝57,每升干菌量22.8g,目的蛋白的表达量占细菌总蛋白的30％,人骨形成蛋白－2成熟肽的理论产率达到3.59g/L。     

表达重组人骨形态发生蛋白-7工程菌的发酵及表达产物的纯化

目的:研究表达重组人骨形态发生蛋白-7工程菌的发酵和表达产物的纯化工艺。方法:利用16L发酵罐发酵培养工程菌,设定了溶氧、搅拌速度、诱导时机、补料和培养基pH值等发酵条件;通过包涵体洗涤、离子交换层析法纯化目的蛋白。结果:工程菌目的蛋白质表达量占菌体总蛋白质的30%以上,纯化后目的蛋白的纯度可达98%。结论:建立了大肠杆菌高效表达人骨形态发生蛋白-7的发酵及纯化工艺。     

大肠杆菌发酵生产重组人颗粒溶素

目的:在FUS-50L生物反应器中利用补料分批培养技术培养表达含重组质粒pET28a( )-GNLY的大肠杆菌BL21(DE3)pLysS株,生产重组颗粒溶素(GNLY)。方法:选取含pET28a( )-GNLY的BL21(DE3)pLysS菌株单个克隆分级培养,将制备的二级种子液接种于发酵罐中。在发酵过程中,控制溶氧为30%～50%,温度为37℃;在基础培养基内生长4h后,补加以甘油为碳源的补料,继续生长到11h;加入葡萄糖至终浓度为1%,30℃诱导表达6h;收集菌体,纯化制备目的蛋白。利用Western印迹检测重组蛋白的抗原性,用CFU方法检测其生物学活性。结果:发酵液中最终菌体密度达80g/L;纯化所得重组蛋白约占菌体总蛋白的5%,含量为60mg/L;经鉴定所获重组颗粒溶素有较好的免疫学活性和生物学活性。结论:用含重组质粒pET28a( )-GNLY的大肠杆菌BL21(DE3)pLysS表达系统,可得到具有生物活性的重组颗粒溶素,为大批量生产提供了条件。     

溶氧反馈分批补料高密度培养人骨形成蛋白-2工程菌

对表达人骨形成蛋白2成熟肽的基因工程大肠杆菌E.coli DH5α/pDH-B²m在500mL摇瓶中进行了培养条件的摸索实验,并在此基础上扩大至NBS Bioflo IV 20L发酵罐,利用溶氧反馈-分批补料培养技术：在培养过程中保持适当的溶解氧（40%）,以溶氧值在线反馈控制搅拌速度及流加补料培养基,使细菌保持适当的比生长率,成功地进行了工程菌的高密度培养,最终菌体密度达OD₆₀₀=57,每升干菌量22.8 g,目的蛋白的表达量占细菌总蛋白的30%,人骨形成蛋白2成熟肽的理论产率达到3.59 g/L。      

重组戊型肝炎病毒衣壳蛋白工程菌的高密度培养

在10L发酵罐中对戊型肝炎病毒衣壳蛋白在重组大肠杆菌中表达发酵工艺进行了研究,用分批培养方法探讨了不同培养基、培养基中磷酸盐浓度和Mg^2＋浓度等因素对菌体生长与重组蛋白表达的影响;用分批补料培养研究了不同的补料工艺对菌体生长与重组蛋白表达的影响,同时对重组菌诱导时期、诱导持续时间以及不同诱导温度表达包含体在尿素溶液中的溶解性进行了研究。结果表明,在优化后的培养基中,磷酸盐浓度、Mg^2＋浓度分别为80mmol/L 与20mmol/L时菌体生长与表达效果较好;分批补料培养中,37℃培养9h菌体达到对数期中期(约45OD600)为适宜诱导时期,加入终浓度为10mmol/L IPTG后诱导5h,OD600达到80以上,重组蛋白表达量达到29.74％,为最适收获菌体时间;37℃表达的包含体80％以上溶解在4mol/L的尿素溶液中,最终浓度达到14mg/mL; 10L发酵罐中确定的发酵工艺参数在30L发酵罐中进行了放大培养,10L发酵罐中确定的发酵工艺参数在30L发酵罐上具有可放大性与重复性, 可以应用于工业生产。     

表达ST1-LTB-a-b融合蛋白基因工程菌株的构建及其免疫原性分析

采用分子生物学技术构建了含有ST1-LTB-a-b融合基因的重组菌株BL21(DE3)(pETST3LTBab), SDS-PAGE和 Western blotting分析表明ST1-LTB-a-b融合基因在大肠杆菌中得到了高效表达, 融合蛋白分子量约为110 kD; 20 L发酵罐培养得到的最佳诱导条件为: 重组菌株以1%接种量、5 L/min通气量培养3 h后加终浓度为0.03 mol/L的乳糖诱导, 通气量升至12.5 L/min继续培养6 h, 表达量占菌体总蛋白的38.53%; 表达的ST1-LTB-a-b融合蛋白无毒性但具有免疫原性, 可以抵抗大肠杆菌和产气荚膜梭菌的感染; 构建的重组菌株BL21(DE3)(pETST3LTBab)有望作为预防仔猪腹泻基因工程疫苗的候选生产菌株。     

蛇毒锯鳞蝰素融合蛋白的发酵与纯化

研究大肠杆菌表达重组蛇毒锯鳞蝰素(Echistatin,Ecs)融合蛋白的发酵和纯化工艺。将Ecs基因插入表达载体pTXB1,转化E.coliBL21(DE3)构建工程菌。对工程菌进行补料分批培养并诱导表达,研究培养基、培养和诱导时间对工程菌生长和目的蛋白表达的影响,几丁质亲和层析纯化Ecs融合蛋白,经DTT裂解后,检测Ecs活性。发酵后菌体湿重可达75g/L,融合蛋白表达量约占总蛋白的35%,重组质粒在BL21宿主菌中传代稳定。亲和层析纯化后,得到Ecs单体,得率为28mg/L发酵液。生物学活性分析显示,重组Ecs能有效抑制血小板的聚集,其活性与天然Ecs相似。优化了Ecs融合基因工程菌的发酵和纯化条件,为规模化生产奠定基础。     

重组尿酸氧化酶发酵工艺优化

目的:优化并获得重组尿酸氧化酶(rUOX)基因工程大肠杆菌BL21(DE3)/pET-32a-uox高密度发酵的工艺参数。方法:在三角摇瓶中进行培养条件的优化实验,分别考察了pH值、接种量、无机盐、碳源、诱导强度等对工程菌生长和重组蛋白表达的影响,得到了优化的发酵条件;在此基础上放大至NBS BIOFLO 110 14 L发酵罐,通过对诱导时机的优化,利用分批补料发酵的方式,使rUOX在高密度培养的条件下得到高表达。结果:在优化的发酵条件下,菌体密度(D600nm)最终达到50以上,相当于20 g/L干重;可溶性rUOX占菌体总蛋白量的45%,其含量达到3.45 g/L。结论:为规模化制备重组黄曲霉尿酸氧化酶奠定了基础。     

GABAA受体蛋白片段在大肠杆菌细胞表达条件研究

为了提高GABAA受体α1蛋白片段在大肠杆菌中表达量,研究了重组菌的发酵条件,包括培养基,接种量,温度,摇床转速,pH,诱导培养时间和诱导剂IPTG使用浓度等对GABAA受体蛋白片段表达的影响。结果表明重组菌以LB培养基为发酵基质,按3%接种量,37℃培养细胞3.5h后IPTG32℃诱导5h,菌体生物量为3.25g/L,目标蛋白表达量达95mg/L。用16L发酵罐进行放大培养,菌体生物量达4.95g/L,发酵周期5.5h。最高目标蛋白表达量达到136mg/L。     

重组有机磷水解酶MPH的发酵条件的优化研究

有机磷水解酶在去除有机磷农药残留中具有重要的应用前景。在Escherichia coli BL21(DE3)中实现了有机磷水解酶(MPH)的重组诱导表达之后,为了实现工业化生产MPH,考察了以乳糖为诱导剂,碳源、氮源、金属离子、培养温度、乳糖浓度及诱导时间等对产酶的影响,得到了优化的发酵条件,L9(34)正交实验进一步确定了最佳的碳源、氮源及乳糖浓度。在此基础上利用7L自控发酵罐进行了发酵过程研究,经12h培养,得到菌体12.65g(DCW)/L,MPH表达量为14.56%,酶活18.69I U/mL。     

脯氨酰内肽酶培养条件的优化及高密度发酵

基因工程菌E.coliBL21/pGEMPEP可以组成型表达重组的点状产气单胞菌脯氨酰内肽酶(PEP),但培养条件极大地影响着酶的产量,为了获得高效表达,首先测定了工程菌表达PEP的稳定性并考察了培养温度、pH、发酵时间、碳源、氮源、无机盐等对产酶的影响,得到了优化的发酵条件,L9(3⁴)正交试验进一步明确了摇床转速、培养温度、pH值、培养时间对产酶量的影响都有高度的统计学意义。在此基础上利用NBSBioFlo3000型5L自控发酵罐进行了高密度、高表达发酵、经20h培养,最终菌体密度达OD₆₀₀60(相当于干菌体225g/L),PEP表达量为28%,每升发酵液中含PEP酶315g。     

High-level expression, purification, and characterization of non-tagged Aspergillus flavus urate oxidase in Escherichia coli

The entire encoding region for Aspergillus flavus uricase was cloned into pET-32a and expressed in Escherichia coli BL21 (DE3). The uricase was expressed in the E. coli cytoplasm in a completely soluble, biologically active form. A scalable process aimed to produce and purify multi-gram quantities of highly pure, recombinant urate oxidase (rUox) from E. coli was developed. The rUox protein was produced in a 30 L fermentor containing 25 L of 2x YT medium and purified to >99% purity using hydrophobic interaction, anion-exchange, and gel filtered chromatography. The final yield of purified rUox from fermentation resulted in approximately 27 g of highly pure, biologically active rUox per kg of cell paste (approximately 238 mg/8.8 g cell paste/L). The results presented here exhibit the ability to generate multi-gram quantities of rUox from E. coli that may be used for the development of pharmaceutics of reducing the hyperuricemia.     

Proteome-based identification of fusion partner for high-level extracellular production of recombinant proteins in Escherichia coli

Extracellular production of recombinant proteins in Escherichia coli has several advantages over cytoplasmic or periplasmic production. However, nonpathogenic laboratory strains of E. coli generally excrete only trace amounts of proteins into the culture medium under normal growth conditions. Here we report a systematic proteome-based approach for developing a system for high-level extracellular production of recombinant proteins in E. coli. First, we analyzed the extracellular proteome of an E. coli B strain, BL21(DE3), to identify naturally excreted proteins, assuming that these proteins may serve as potential fusion partners for the production of recombinant proteins in the medium. Next, overexpression and excretion studies were performed for the 20 selected fusion partners with molecular weights below 40 kDa. Twelve of them were found to allow fused proteins to excrete into the medium at considerable levels. The most efficient excreting fusion partner, OsmY, was used as a carrier protein to excrete heterologous proteins into the medium. E. coli alkaline phosphatase, Bacillus subtilis alpha-amylase, and human leptin used as model proteins could all be excreted into the medium at concentrations ranging from 5 to 64 mg/L during the flask cultivation. When only the signal peptide or the mature part of OsmY was used as a fusion partner, no such excretion was observed; this confirmed that these proteins were truly excreted rather than released by outer membrane leakage. The recombinant protein of interest could be recovered by cleaving off the fusion partner by enterokinase as demonstrated for alkaline phosphatase as an example. High cell density cultivation allowed production of these proteins to the levels of 250-700 mg/L in the culture medium, suggesting the good potential of this approach for the excretory production of recombinant proteins.     

炭疽杆菌噬菌体裂解酶基因在大肠杆菌中的表达及鉴定

利用PCR方法扩增炭疽杆菌噬菌体裂解酶 (γlysin)基因 ,克隆至大肠杆菌表达载体pET2 2b中 ,经菌落PCR筛选、序列测定和酶切鉴定证实表达载体pET22b-γlysin构建成功 ,并在EscherichiacoliBL21(DE3)中获得了高表达。目的蛋白约占菌体总蛋白的40% ,5L发酵罐中的产酶水平高达 15g L。菌体经超声破碎 ,制备无细胞抽提液 ,StreamlineSP和SPHP柱层析以及SephacrylS-100凝胶过滤三步纯化 ,得到分子量为 2 7kD单一条带的目的蛋白 ,薄层扫描分析显示其纯度大于 95 %。目的蛋白的收率为19.1% ,纯化倍数为350。生物活性鉴定重组的γ噬菌体裂解酶具有特异性 :可快速裂解炭疽杆菌 ,比活为 1400u mg左右 ;而对大肠杆菌、枯草杆菌及蜡样芽孢杆菌没有裂解活性。     

基因重组大肠杆菌表达HrpNEcc蛋白的发酵条件及诱导条件优化

对已构建好的表达HrpNEcc蛋白的工程菌BL21(DE3)/pET30a(+)hrpN Ecc的摇瓶发酵条件及乳糖诱导进行优化, 通过在7L发酵罐中放大发酵实验,以期提高蛋白产量并降低生产成本。在摇瓶中优化的发酵及诱导条件是：5% 的接种量,TB培养基,菌体培养至对数生长前期,添加3g/L外源诱导剂乳糖时,HrpNEcc蛋白产量可达417.60mg/L,比不添加乳糖时提高了36.73%,比用IPTG诱导时提高了16.85%。7L发酵罐中发酵,获得菌体湿重达到57.24g/L（WCW）,可溶性HrpNEcc蛋白产量占细胞总蛋白的50.2%,为3.29 g/L。     

Excretion of human beta-endorphin into culture medium by using outer membrane protein F as a fusion partner in recombinant Escherichia coli

Escherichia coli BL21 strains were found to excrete a large amount of outer membrane protein F (OmpF) into culture medium during high-cell-density cultivation. From this interesting phenomenon, a novel and efficient OmpF fusion system was developed for the excretion of recombinant proteins by E. coli. The ompF gene of E. coli BL21(DE3) was first knocked out by using the red operon of bacteriophage lambda to construct E. coli MBEL-BL101. For the excretion of human beta-endorphin as a model protein, the beta-endorphin gene was fused to the C terminus of the E. coli ompF gene by using a linker containing the Factor Xa recognition site. To develop a fed-batch culture condition that allows efficient production of OmpF-beta-endorphin fusion protein, three different feeding strategies, an exponential feeding strategy and two pH-stat strategies with defined and complex nutrient feeding solutions, were examined. Among these, the pH-stat feeding strategy with the complex nutrient feeding solution resulted in the highest productivity (0.33 g of protein per liter per h). Under this condition, up to 5.6 g of OmpF-beta-endorphin fusion protein per liter was excreted into culture medium. The fusion protein was purified by anion-exchange chromatography and cleaved by Factor Xa to yield beta-endorphin, which was finally purified by reverse-phase chromatography. From 2.7 liters of culture supernatant, 545.4 mg of beta-endorphin was obtained.     

重组人血管内皮抑制素（rh-Endostatin）大肠杆菌表达体系发酵条件的优化

优化了重组人血管内皮抑制素的E. coli表达体系的发酵条件。利用E. coli表达体系得到了较高的产量,在9h左右的发酵周期内达到OD600值140,包涵体蛋白产量为3 g/L。主要优化了异丙基-β-D-硫代半乳糖苷（Isopropyl-β-D-thiogalactopyranoside, IPTG）的终浓度、诱导时间、培养温度、补料控制方法等条件,并且在诱导后提高培养温度到40℃,在非常短的培养周期内达到了高密度培养的目的。利用E. coli表达,继而通过复性获得有活性的重组人血管内皮抑制素,成本低、生产过程稳定可控、得到的蛋白性质稳定,符合工业生产的需要。